OTTAWA, Aug. 21 /PRNewswire/ -- Epocal, Inc., a leading edge provider of point of care technology, announced today that it has received U.S. Food and Drug Administration (FDA) clearance to market its new glucose test on the epoc Blood Analysis System. Glucose measurements are used for the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus and idiopathic hypoglycemia, and of pancreatic islet cell tumors. The addition of glucose to the epoc BGEM Test Card, which includes in vitro diagnostic tests for pH, pO2, pCO2, Na, K, iCa and Hct (plus calculated values), further expands the clinical utility of the Company's point of care blood gas and electrolyte platform.
"The FDA clearance of glucose represents one of many milestones to come for Epocal and for healthcare as we continue to expand the test menu of the first wireless and cost effective point of care testing system." said Imants Lauks, Epocal President and Founder. "We are very excited to offer an award winning technology that enables hospitals worldwide to improve the delivery of patient care, reduce their operating expenses and operate more efficiently."
About Epocal, Inc.
Epocal, Inc., headquartered in Ottawa, ON, Canada with U.S. Sales and Marketing operations located in Horsham, PA, develops, manufactures and markets the epoc Blood Analysis System. epoc (enterprise point of care) is healthcare's first cost effective point of care testing solution to leverage SmartCard(TM) technology and the power of wireless communication to provide critical caregivers with real-time, laboratory quality test results at the patient's bedside.
Additional information about the epoc System and Epocal, Inc. is available on the Company's website - www.epocal.com